Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic.

Giuseppe MagroStefania BaroneFederico TostoAntonio De MartinoDomenico Santange LoLucia Manzo Angelo PascarellaPietro BrunoMarilisa PasqualeAntonio GambardellaPaola Valentino

Published in: Journal of neurology (2022)

Adopting an extended interval dosing does not result in significantly different occurrence of WoS between the ExID and the StID populations, in our cohort of patients. Interestingly, there is a strong correlation between WoS and a higher EDSS and FSS. Safety and efficacy of Natalizumab with ExID are relatively preserved in our study.

Keyphrases

sars cov
multiple sclerosis
end stage renal disease
ejection fraction
newly diagnosed
coronavirus disease
risk assessment
peritoneal dialysis
prognostic factors
sleep quality
physical activity
patient reported outcomes